NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal [Committee B] meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 4 November 2021

**Location:** Zoom Video Conference

# Committee members present:

1. Professor Amanda Adler [Chair] Present for all items
2. Dr Sanjeev Patel [Vice Chair] Present for all items
3. Ms Anna Pracz Present for all items
4. Ms Denice Bryceland Present for items 1 to 5.2.3
5. Professor Iolo Dull Present for all items
6. Dr James Fotheringham Present for all items
7. Dr Mark Glover Present for all items
8. Ms Mary Weatherstone Present for all items
9. Dr Nicholas Latimer Present for all items
10. Professor Nicky Welton Present for all items
11. Mr Nigel Westwood Present for all items
12. Mr Peter Wheatley Price Present for all items
13. Dr Rhiannon Owen Present for all items
14. Professor Sarah Wild Present for all items
15. Dr Stephen Smith Present for all items
16. Mr Toby Smith Present for all items
17. Mr Tony Wootton Present for all items
18. Dr Veline L’Esperance Present for all items
19. Dr Charles Crawley Present for all items

# NICE staff present:

Catherine Pank, Assistant Present for items 1 to 3.2.2

project manager

Ella Livingstone, Technical Present for all items

adviser – commercial risk assessment

Emily Eaton Turner, Technical Present for all items

adviser – commercial risk assessment

Emily Leckenby, HTA Analyst Present for all items

Heidi Livingstone, Senior Present for items 1 to 5.2.2

public involvement adviser

Korin Knight, Appraisal Present for all items

editor

James Devine, Coordinator Present for all items

Philip Williams, Finance / Present for all items

business analyst

Rosalee Mason, Coordinator - Present for all items

corporate office

Shonagh D’Sylva, Project Present for items 5 to 5.2.2

manager

Daniel Davies, Project Present for 1 to 4.2.2 and 6 to 6.2.2

manager

Emma Gordon, Administrator Present for 1 to 4.2.2 and 6 to 6.2.2

Richard Diaz, Associate Present items 1 to 4.2.2 and 6 to 6.2.2

director

Ewa Rupniewska, Technical Present for items 1 to 3.3.2

advisor

Lorna Dunning, Technical Present for items 4 to 4.2.2

advisor

Ross Wilkinson, Technical Present for items 4 to 4.2.2

advisor

Henry Edwards, Associate Present for items 5 to 5.2.2

director

Harsimran Sarpal, Technical Present for items 5 to 5.2.2

analyst

Charlie Hewitt, Technical Present for items 5 to 5.2.2

Advisor

Adam Brooke, Technical

advisor Present for items 6 to 6.2.2

Emily Leckenby, Technical Present for items 6 to 6.2.2

analyst

# External group representatives present:

Dr Graham Scotland, Aberdeen Present for items 1 to 3.1.3

HTA group

Dr Neil Scott, Aberdeen Present for items 1 to 3.1.3

HTA group

Joanne Lord, Southampton Present for items 4 to 4.1.3

HTA group

Geoff Frampton, Southampton Present for items 4 to 4.1.3

HTA group

Robert Wolff, Kleijnen Present for items 5 to 5.2.2

Systematic Reviews ltd

Pim Wetzelaer, Kleijnen Present for items 5 to 5.2.2

Systematic Reviews ltd

# Clinical & patient experts present:

Sarah Baker, Campaign manager Present for items 1 to 3.1.3

for Anaphylaxis campaign - nominated

by anaphylaxis now

Hannah Bell, Information officer Present for items 1 to 3.1.3

for anaphylaxis campaign - nominated

by anaphylaxis now

Professor Peter Clark, NHS Present for items 4 to 4.2.2

England cancer drug fund lead

Dr Zoe Paskins, Senior lecturer Present for items 5 to 5.2

and hon. consultant rheumatologist,

Keele university – nominated by

British society for rheumatology

Dr Nicola Peel, Consultant in Present for items 5 to 5.2

metabolic bone medicine, Sheffield

teaching hospitals NHS foundation trust –

nominated by Royal osteoporosis society

Mayrine Fraser, Service Present for items 5 to 5.2

improvement lead, Royal osteoporosis

society – nominated by Royal osteoporosis

society

Christine Sharp, Volounteer, Present for items 5 to 5.2

Royal osteoporosis society – nominated

by Royal osteoporosis society

Brian O’Toole, PenTAG Present for items 6 to 6.2

Professor G.J. Mendelez-Torres, Present for items 6 to 6.2

PenTAG

# Observers present:

Catherine Spanswick, Technical Present for all items

analyst, NICE

1. Introduction to the meeting
	1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
	1. None.
3. Appraisal of Palforzia for treating peanut allergy [ID1282]
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Aimmune Therapeutics
		2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr James Fotheringham declared a non-specific direct financial interest. Both he and his organisation have received fees from Novartis, a listed comparator company, for predictive tools related to solid state organ transplantation.
- It was agreed that this declaration would not prevent Dr Fotheringham from participating in this discussion
	+ 1. The Chair then introduced the lead team Dr Nicholas Latimer (cost lead), Dr Veline L’Esperance (clinical lead), and Mr Tony Wootton (lay lead), who gave presentations on the clinical effectiveness and cost effectiveness of Palforzia for treating peanut allergy [ID1282]
	1. Part 2b – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting]
		1. The committee then agreed on the content of the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] or Final Appraisal Determination [FAD] in line with their decisions.

A document summarising the recommendations and committee’s considerations will be available here:

1. https://www.nice.org.uk/guidance/indevelopment/gid-ta10713/documentsEvaluation of Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Janssen-Cilag
		2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Mr Peter Wheatley-Price declared a direct financial interest as his employer works with Takeda who manufacture ixazomib, which is used with lenalidomide and dexamethasone in a variety of indications in Multiple Myeloma. It recently completed a trial for newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant but does not yet have a licence.
 - It was agreed that this declaration would not prevent Mr Wheatley-Price from participating in this discussion

 No further conflicts of interest were declared for this item.

* + 1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.
		2. The committee discussed confidential information submitted for this item.
	1. Part 2b – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting].
		1. The committee then agreed on the content of the Final Appraisal Determination [FAD]. The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.

 A document summarising the recommendations and committee’s considerations will be available here:

 https://www.nice.org.uk/guidance/indevelopment/gid-ta10449/documents

1. Appraisal of Romosozumab for treating severe osteoporosis [ID3936]
	1. Part 1 – Open session
		1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from UCB Pharma
		2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr James Fotheringham declared a non-specific direct financial interest. Both he and his organisation have received fees from Novartis, a listed comparator company, for predictive tools related to solid state organ transplantation.
- It was agreed that this declaration would not prevent Dr Fotheringham from participating in this discussion
* Dr Nicholas Latimer declared a non-specific financial interest as since May 2021 he has been a member of the ScHARR team for a consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are listed as a comparator company. Additionally he declared that he has given Novartis staff training on survival analysis in October 2021, but this was not product or appraisal specific and was about methods.
- It was agreed that these declarations would not prevent Dr Latimer from participating in this discussion
* Dr Zoe Paskins declared a direct financial interest, as the British Society of Rheumatology, her nominating organisation, receives funding for its registers from Amgen, Eli Lily and Sandoz.
Additionally the British Society of Rheumatology received sponsorship funding from Eli Lily for its case-based conference in October 2020, and from UCB Pharma, Amgen, Eli Lily, and Novartis for its 2021 annual conference
- It was agreed that these declarations would not prevent Dr Paskins from participating in this discussion.
* Dr Nicola Peel declared a direct financial interest, as she has received funding from UCB Pharma who sponsored 3 clinical network meetings, provided a grant to support public advocacy and affairs programmes, funded a webinar series on fracture prevention, and provided funding for costs associated with developing a RCGP module. Dr Peel also declared an indirect financial interest as she has received funding from Amgen, a listed comparator company, who sponsored 3 clinical network meetings and provided a grant to support public advocacy and affairs programmes.
- It was agreed that these declarations would not prevent Dr Peel from participating in this discussion.
* Maryine Fraser declared a specific financial interest as her employer, the Royal Osteoporosis Society, have received funding from UCB Pharma, and they have also sponsored 3 clinical network meetings.
- It was agreed that these declarations would not prevent Mayrine from participating in this discussion.
* Christine Sharp declared a specific financial interest as she is a volunteer for the Royal Osteoporosis Society, which has received funding from UCB Pharma who sponsored 3 clinical network meetings, provided a grant to support public advocacy and affairs programmes, funded a webinar series on fracture prevention, and provided funding for costs associated with developing a RCGP module. Additionally, the Royal Osteoporosis Society has received funding from Amgen, a listed comparator company, for 3 clinical network meetings, and a grant to support public advocacy and affairs programmes
- It was agreed that these declarations would not prevent Christine from participating in this discussion.

 No further conflicts of interest were declared for this item.

* + 1. The Vice Chair then introduced the lead team Rhiannon Owen (cost lead), Charles Crawley (clinical lead), and Nigel Westwood (lay lead), who gave presentations on the clinical effectiveness and cost effectiveness of Romosozumab for treating severe osteoporosis [ID3936]
	1. Part 2 – Closed session [members of the public, company representatives, clinical and patient experts were asked to leave the meeting]
		1. The committee discussed confidential information submitted for this item.
		2. The committee then agreed on the content of the Appraisal Consultation Document [ACD]. The committee decision was reached by consensus.
		3. The committee asked the NICE technical team to prepare the Appraisal Consultation Document [ACD] in line with their decisions.

 A document summarising the recommendations and committee’s considerations will be available here:

 https://www.nice.org.uk/guidance/indevelopment/gid-ta10828/documents

1. Evaluation of Ponesimod for treating relapsing multiple sclerosis [ID1393]
	1. Part 1 – Open session
		1. The Vice Chair welcomed the invited clinical expert, external group representatives, members of the public and company representatives from Janssen
		2. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* No conflicts of interest were declared for this item
	+ 1. The Vice Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.
	1. Part 2b – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting].
		1. The committee then agreed on the content of the Final Appraisal Determination [FAD]. The committee decision was reached by consensus..
		2. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.

 A document summarising the recommendations and committee’s considerations will be available here:

 https://www.nice.org.uk/guidance/indevelopment/gid-ta10556/documents

1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee B) will be held on Wednesday 8 December 2021 and will start promptly at 9:30am.